Professional manufacture steroid powders , Injection steroid liquid , Peptides , HGH176-191, Sarms , Pharmaceutical raw materials ( Phenacetin ) , GBL , Local anesthetics , BB , BA etc.

Send Me The Latest Product Alerts
(No SPAM - We would not sell or share your e-mail address.)
  • Product Details

Medical API Active Pharmaceutical Ingredients

Medical API Active Pharmaceutical Ingredients

Large Image :  Medical API Active Pharmaceutical Ingredients

Verified Supplier


Verified Supplier


Detailed Product Description
CAS NO.: 78755-81-4 Synonyms: Anexate, Flumazenilo, Flumazenilum, Flumazepil, Lanexat
Category: Active Pharmaceutical Ingredients Brand: NJBNsteroid
MF: C15H14FN3O3 MW: 303.29
MOQ: 5g Presentation: White Crystalline Powder
Skype: Bnsteroid
High Light:

active pharma ingredients


pharmaceutical raw material

Medical API Active Pharmaceutical Ingredients Flumazenil Romazicon 78755-81-4

Flumazenil (Romazicon) Half life
Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).
Flumazenil (Romazicon)  Functions

  1. Flumazenil is of benefit in patients who become excessively drowsy after benzodiazepines are used for either diagnostic or therapeutic procedures.
  2. It has been used as an antidote in the treatment of benzodiazepine overdoses It reverses the effects of benzodiazepines by competitive inhibition at the benzodiazepine binding site on the GABAA receptor. There are many complications that must be taken into consideration when used in theacute care setting.
  3. It has also been used in hepatic encephalopathy, though results have been mixed.

Flumazenil (Romazicon) Specifications


Product name Flumazenil (Romazicon)


Anexate, Flumazenilo, Flumazenilum, Flumazepil, Lanexat



Category Active Pharmaceutical Ingredients





Structural Formula

Medical API Active Pharmaceutical Ingredients

Melting point

201-203º C

Water solubility



White crystalline powder



Loss On Drying

≤ 5%

Sulphated Ash

≤ 5%

Heavy Metals

≤ 10PPM

Total microbacterial count

NMT 1000cfu/g




1kg/ foil bag or as you wish


Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.

Shelf Life

Two years when properly stored

Brand NJBNsteroid
Company Nanjing Bangnuo Biotechnology Co., Ltd

Flumazenil: a benzodiazepine antagonist.
The mechanism of action, pharmacokinetics, and use of flumazenil in benzodiazepine overdose, as well as in the management of other disease states, are reviewed. Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists.
Flumazenil has been studied for a variety of indications, including as an antidote to benzodiazepine overdose and for awakening of comatose patients, reversal of sedation after surgery and in critically ill patients, and management of hepatic encephalopathy. It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy. It appears to be effective in reversing sedation induced by midazolam or diazepam, and case reports suggest that it is useful in awakening comatose patients, although its clinical utility is questionable.
Flumazenil has proved useful in reversing conscious sedation in critically ill patients, although response may be dose dependent. Animal models indicate that flumazenil is of some benefit in hepatic encephalopathy, but until well-designed clinical trials are conducted, hepatic encephalopathy must be considered an investigational indication for flumazenil. Adverse reactions include CNS manifestations, resedation, cardiovascular effects, seizures, and alterations in intracranial pressure and cerebral perfusion pressure. Hepatic dysfunction results in a substantial change in the pharmacokinetic profile of flumazenil; therefore, dosage adjustment may be necessary in patients with hepatic dysfunction or in those receiving medications that alter flumazenil metabolism. Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected. It may be beneficial after surgery when benzodiazepines have been used as part of anesthesia and after a diagnostic or surgical procedure when assessment of CNS function is necessary.
More Pharmaceutical Intermediates (Inhibitors) 


NO. Product Name CAS NO.
1 Afatinib (BIBW 2992) 439081-18-2
2 Axitinib 319460-85-0
3 Erlotinib 183321-74-6
4 Esomeprazole magnesium 161973-10-0
5 Esomeprazole sodium 161796-78-7
6 Obeticholic Acid 459789-99-2
7 Olaparib 763113-22-0
8 Omeprazole 73590-58-6
9 Ufiprazole 73590-85-9
10 Otilonium bromide 26095-59-0
11 Bortezomib 179324-69-7
12 Pristimerin 1258-84-0
13 Unii-U2Y5ofn795 649735-63-7
14 Hesperidin 520-26-3
15 Dabrafenib (GSK2118436) 1195765-45-7
16 Vatalanib base 212141-54-3
17 Skype bnsteroid
18 Email

Welcome to our website,  we are ready to serve you! 
Medical API Active Pharmaceutical Ingredients

Contact Details
Nanjing Bangnuo Biotechnology Co., Ltd

Contact Person: CPSS

Tel: +8617327093119

Send your inquiry directly to us (0 / 3000)